GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Return-on-Tangible-Asset

Q BioMed (Q BioMed) Return-on-Tangible-Asset : -90.35% (As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Q BioMed's annualized Net Income for the quarter that ended in Feb. 2023 was $-2.89 Mil. Q BioMed's average total tangible assets for the quarter that ended in Feb. 2023 was $3.20 Mil. Therefore, Q BioMed's annualized Return-on-Tangible-Asset for the quarter that ended in Feb. 2023 was -90.35%.

The historical rank and industry rank for Q BioMed's Return-on-Tangible-Asset or its related term are showing as below:

QBIO's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.065
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Q BioMed Return-on-Tangible-Asset Historical Data

The historical data trend for Q BioMed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Return-on-Tangible-Asset Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -526.16 -712.16 -6,533.66 -2,416.72 -111.67

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,778.76 -2,947.25 -1,927.27 541.49 -90.35

Competitive Comparison of Q BioMed's Return-on-Tangible-Asset

For the Biotechnology subindustry, Q BioMed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q BioMed's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Q BioMed's Return-on-Tangible-Asset falls into.



Q BioMed Return-on-Tangible-Asset Calculation

Q BioMed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Nov. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Nov. 2022 )  (A: Nov. 2021 )(A: Nov. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Nov. 2022 )  (A: Nov. 2021 )(A: Nov. 2022 )
=-2.052/( (0.459+3.216)/ 2 )
=-2.052/1.8375
=-111.67 %

Q BioMed's annualized Return-on-Tangible-Asset for the quarter that ended in Feb. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Feb. 2023 )  (Q: Nov. 2022 )(Q: Feb. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Feb. 2023 )  (Q: Nov. 2022 )(Q: Feb. 2023 )
=-2.888/( (3.216+3.177)/ 2 )
=-2.888/3.1965
=-90.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2023) net income data.


Q BioMed  (OTCPK:QBIO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Q BioMed Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Q BioMed's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1